Premarket Approval: Fda Medical Device Counsel

Federal Food, Drug, and Cosmetic Act (FDCA, 21 U.S.C. § 301 et seq.) as amended by Medical Device Amendments 1976 establishes three-tier device classification based on risk and required controls. Class I devices (low risk) face general controls including establishment registration, device listing, and 21 C.F.R. § 820 Quality System Regulation. Class II devices (moderate risk) require general plus special controls (typically 510(k) clearance demonstrating substantial equivalence). Class III devices (life-sustaining/supporting or pose significant risk) require Premarket Approval under 21 U.S.C. § 360e providing reasonable assurance of safety and effectiveness. Our FDA regulatory compliance practice handles device classification analysis, predicate device research, and pathway selection at the earliest pre-submission stage.

PMA applies to Class III devices without legally marketed predicate, novel device types, and devices requiring affirmative safety/effectiveness demonstration through original clinical data. 510(k) premarket notification applies when device demonstrates substantial equivalence to legally marketed predicate device under Lohr v. Medtronic, 518 U.S. 470 (1996) framework. De Novo classification under 21 U.S.C. § 360c(f)(2) provides risk-based pathway for novel low-to-moderate risk devices avoiding automatic Class III designation. 21st Century Cures Act 2016 Breakthrough Devices Program offers expedited review and interactive communication for life-threatening or irreversibly debilitating condition devices. Our FDA product registration practice maps optimal regulatory pathway, predicate analysis, and Breakthrough Designation strategy as the foundational regulatory decision.

PMA approval requires "valid scientific evidence" of safety and effectiveness typically demonstrated through pivotal randomized controlled trials with adequate statistical power for primary endpoints. Investigational Device Exemption (IDE) under 21 C.F.R. § 812 authorizes clinical investigation with FDA approval, IRB oversight, and informed consent for Significant Risk (SR) devices. Pre-Submission (Q-Sub) meetings under FDA 2017 guidance enable sponsor-FDA dialogue on trial design, primary endpoints, and analysis methodology before IDE filing. Real-World Evidence (RWE) under 21st Century Cures Act 2016 supplements traditional RCT data with registry data, claims databases, and EHR-derived evidence for selected approvals. Effective FDA drug approval process framework adapts to device pivotal trial design, Pre-Sub strategy, and FDA Type C meeting coordination.

PMA application under 21 C.F.R. § 814.20 includes 16 sections covering device description, manufacturing information, indications, alternative practices, marketing history, and clinical investigations summary. Modular PMA submission allows sponsors to submit completed sections sequentially with FDA preliminary review of each module before complete submission. PMA review timeline targets 180 days (statutory) but average 8-15 months including FDA major deficiency letters and sponsor amendments. Advisory committee meeting under 21 C.F.R. § 814.44(a)(2) involves panel of outside experts reviewing PMA for high-risk or novel devices providing recommendations to FDA. Our defective medical devices team coordinates PMA submission strategy, advisory committee preparation, and major deficiency response throughout the approval lifecycle.

Quality System Regulation (QSR) under 21 C.F.R. § 820 establishes design controls, document controls, purchasing controls, production controls, and CAPA (Corrective and Preventive Action) requirements for device manufacturers. Quality Management System Regulation (QMSR) Final Rule (published February 2024, effective February 2026) harmonizes 21 C.F.R. § 820 with ISO 13485:2016 international standard. QSIT (Quality System Inspection Technique) under FDA Investigations Operations Manual focuses on Management Controls, Design Controls, CAPA, and Production/Process Controls subsystems. Form 483 observations follow QSIT inspection identifying non-compliance with warning letter escalation when systemic deficiencies remain unaddressed. Our government regulatory compliance practice prepares QSR/QMSR audit responses, CAPA remediation plans, and parallel inspection management strategy.

PMA supplements under 21 C.F.R. § 814.39 govern post-approval device modifications with submission type (180-Day, Real-Time, Special, 30-Day Notice) determined by change significance and safety impact. Medical Device Reporting (MDR) under 21 C.F.R. § 803 requires reporting of deaths within 10 days, serious injuries within 30 days, and malfunctions causing or contributing to serious injury within 30 days. Post-Approval Studies (PAS) ordered as PMA condition track long-term device performance with FDA conducting Quarterly Progress Reports and Final Reports review. Annual reports under § 814.84 summarize manufacturing changes, MDRs, and post-approval study progress for FDA ongoing oversight. Strong EU life sciences regulatory coordination synchronizes FDA MDR reporting with EU MDR/IVDR reporting, providing unified global vigilance reporting framework.

FDA Warning Letter follows Form 483 inspection observations when significant violations remain unresolved with 15-business-day response requirement and public disclosure on FDA website. Persistent or escalating non-compliance triggers DOJ consent decree litigation seeking permanent injunction under FDCA § 302 (21 U.S.C. § 332) with operational restrictions and FDA-approved expert oversight. Recent consent decrees against major device manufacturers (medical device sterilizer manufacturers, contact lens manufacturers) demonstrate consent decree scope and ongoing compliance burden. Import alerts under FDCA § 801 (21 U.S.C. § 381) detain imported products at port pending compliance verification creating substantial supply chain disruption. Our defective drugs team manages warning letter response strategy, consent decree negotiation, and import alert challenge throughout escalating enforcement.

Riegel v. Medtronic, 552 U.S. 312 (2008) established express federal preemption under MDA § 521 (21 U.S.C. § 360k) of state common law claims challenging PMA-approved device design and labeling. Preemption applies when (1) FDA established device-specific requirements through PMA process and (2) state law would impose requirements different from or in addition to federal requirements. Stengel v. Medtronic, 704 F.3d 1224 (9th Cir. 2013) and Bausch v. Stryker recognize "parallel claims" exception; state law claims paralleling federal requirements survive preemption. Failure to warn claims, manufacturing defect claims (parallel to QSR violations), and off-label promotion claims navigate preemption boundary with substantial circuit variation. The post-Riegel framework requires our federal regulatory changes team to integrate FDA approval records, MDR submissions, and design history documentation as central preemption defense evidence.

PMA review timeline is 180 days statutory but actual average is 8-15 months including FDA major deficiency letters and sponsor amendments. Pre-Submission meetings, modular submissions, and Breakthrough Devices designation can compress timeline. Total development-to-approval timeline (including clinical trials) typically spans 3-7 years for novel Class III devices.

FDA can withdraw PMA approval under 21 U.S.C. § 360e(e) if device proves unsafe or ineffective, new evidence shows manufacturer made material misrepresentation, or labeling becomes false or misleading. Recent withdrawals tied to post-approval study failures, persistent safety signals from MDR reports, or systemic QSR violations. Approval withdrawal differs from voluntary recall (manufacturer-initiated) and FDA-mandated recall under FDCA § 518 (21 U.S.C. § 360h).

Yes. Riegel v. Medtronic (2008) established express preemption of state common law claims challenging PMA-approved design and labeling under MDA § 521. However, "parallel claims" alleging state law violations that mirror federal requirements survive preemption per Stengel v. Medtronic (2013). Manufacturing defect claims tied to QSR violations, failure to comply with reporting requirements, and off-label promotion claims are typically not preempted.